Invests in categories: BiotechDevelopmentDrugHealthcareHealthTechMedtechPlatformProductTechnologyTherapeutics
RA Capital
Portfolio
211
Persons
101
Mentions
196
Employees: 11-50
Investment Stage: Seed; Series A; Series B; Series C
Portfolio 211
Show more
Persons 101
| Date | First Name | Last Name | Title | Location | |||
| - | HENRY | STUSNICK | Analyst | - | - | - | |
| - | JAKOB | LEX | Strategic ... | - | - | - | |
| - | KELLEN | KINSELLA | Research A... | - | - | - | |
| - | WALTER | DAUKSHER | Associate,... | - | - | - | |
| - | RAJEEV | SHAH | Managing P... | - | - | - | |
| - | NIKITA | SHETTY | Data Analy... | - | - | - | |
| - | CHARLOTTE | WANG | Senior Pro... | - | - | - | |
| - | ALEX | BECKER, Ph... | Quantitati... | - | - | - | |
| - | LINDSEY | RAMSDELL | Research A... | - | - | - | |
| - | XINZHE | FANG, MBA | Associate | - | - | - | |
| - | ANTHONY | CHIU, PhD | Associate | - | - | - | |
| - | MONICA | STANCIU, P... | Director | - | - | - | |
| - | JEDEDIAH | SELTZER, P... | Associate ... | - | - | - | |
| - | MATTHEW | HAMMOND, P... | Partner | - | - | - | |
| - | ELENA | RUBINI | Associate | - | - | - | |
| - | DANIEL | BAHCHELI | Director, ... | - | - | - | |
| - | KATE | MOREAU, Ph... | Director | - | - | - | |
| - | GRACE | MAGGIACOMO | Research M... | - | - | - | |
| - | JAIMIE | KIRKPATRIC... | Senior Res... | - | - | - | |
| - | JAMES | LYON | Research A... | - | - | - | |
| - | AMI | THAKRAR, P... | Associate | - | - | - | |
| - | KRITI | SUBRAMANYA... | Senior Ass... | - | - | - | |
| - | NANDITA | SHANGARI, ... | Managing D... | - | - | - | |
| - | YASH | CHALASANI,... | Associate | - | - | - | |
| - | CHERI | DONNELLY | Research A... | - | - | - | |
| - | JUSTIN | WANEY | Vice Presi... | - | - | - | |
| - | JONATHAN | PRITZ, PhD | Investment... | - | - | - | |
| - | ERICH | SCHELLER, ... | Executive ... | - | - | - | |
| - | GORHAM | PARTINGTON | Senior Res... | - | - | - | |
| - | NICK | PICCA, MBA | Associate,... | - | - | - | |
| - | JAKE | SIMSON, Ph... | Partner | - | - | - | |
| - | ELIZABETH | JOCHUM, Ph... | Director o... | - | - | - | |
| - | JULIE | GUPTA, PhD | Associate | - | - | - | |
| - | ALANA | MACDONALD,... | Senior Ass... | - | - | - | |
| - | ALEX | MILLER, Ph... | Senior Ass... | - | - | - | |
| - | JENNA | HEBERT, Ph... | Investment... | - | - | - | |
| - | REBECCA | SILBERMAN,... | Investment... | - | - | - | |
| - | SAHIBA | BAVEJA | Associate,... | - | - | - | |
| - | VINCE | MIAO, PhD | Senior Ass... | - | - | - | |
| - | SEBASTIAN | HUAYAMARES... | Associate | - | - | - | |
| - | BRIAN | BISSELL | Senior Ass... | - | - | - | |
| - | BEAR | ZHANG, PhD | Associate | - | - | - | |
| - | CAITLIN | BLINKHORN | Senior Res... | - | - | - | |
| - | VICTORIA | BLAKE, PhD | Associate | - | - | - | |
| - | CHEYI | LI | Research A... | - | - | - | |
| - | TIM | HOWARD, Ph... | Senior Inf... | - | - | - | |
| - | ADAM | KAYE | Senior Man... | - | - | - | |
| - | BREANNA | O'REILLY, ... | Analyst | - | - | - | |
| - | LAURA | TADVALKAR,... | Managing D... | - | - | - | |
| - | KUNAL | RAYAKAR, M... | Associate | - | - | - | |
| - | EMORY | WERNER, MD | Senior Ass... | - | - | - | |
| - | NICK | SURDEL | Associate | - | - | - | |
| - | MAX | DENIES, Ph... | Analyst | - | - | - | |
| - | ASTHA | BILIMORIA | Senior Dat... | - | - | - | |
| - | JOHN | AVERILL, M... | Associate | - | - | - | |
| - | TESS | CAMERON | Managing D... | - | - | - | |
| - | DAWEI | ZHANG, PhD | Associate | - | - | - | |
| - | ANDREW | CHAN | Junior Ass... | - | - | - | |
| - | RICHARD | XIE, PhD | Senior Hea... | - | - | - | |
| - | DEREK | DiROCCO, P... | Partner | - | - | - | |
| - | MEGAN | LIPCSEY, M... | Investment... | - | - | - | |
| - | CRISTINA | MONTERO, P... | Director | - | - | - | |
| - | SHAN | SHAN WANG,... | Associate ... | - | - | - | |
| - | NEIL | PATEL | Associate | - | - | - | |
| - | MICHAEL | CHAN | Primary Ma... | - | - | - | |
| - | LINDSEY | ROSS | Research A... | - | - | - | |
| - | FUAD | NASER, PhD | Analyst | - | - | - | |
| - | PETER | BALOGH | Analyst | - | - | - | |
| - | LAURA | STOPPEL, P... | Partner | - | - | - | |
| - | JEREMY | LACK, DPhi... | Partner | - | - | - | |
| - | JENNIFER | ZHU | Junior Ass... | - | - | - | |
| - | CHLOE | TAMIS | Research A... | - | - | - | |
| - | PRITHVIRAJ | SINGHA ROY... | Analyst | - | - | - | |
| - | JOSH | RESNICK, M... | Partner | - | - | - | |
| - | ANDREW | LEVIN, PhD... | Partner | - | - | - | |
| - | SANTIAGO | ACERO-BEDO... | Associate | - | - | - | |
| - | ANURAG | KONDAPALLI | Principal | - | - | - | |
| - | ADAM | PRINCE, MD... | Associate | - | - | - | |
| - | KELCEE | EVERETTE, ... | Associate | - | - | - | |
| - | ABIGAIL | SCHMITZ, P... | Senior Ass... | - | - | - | |
| - | EMILY | KELTY | Analyst, Q... | - | - | - | |
| - | ALYSSA | LARSON, Ph... | Director, ... | - | - | - | |
| - | ANA | CASTRO | Venture An... | - | - | - | |
| - | ALEX | MARTINEZ-F... | Director, ... | - | - | - | |
| - | NISHI | JAIN | Associate | - | - | - | |
| - | SARAH | NESHAT, Ph... | Associate | - | - | - | |
| - | TYLER | CARNEY | Associate,... | - | - | - | |
| - | EMILY | MINKOW, MB... | Managing D... | - | - | - | |
| - | ZACH | SCHEINER, ... | Partner | - | - | - | |
| - | DAVIS | BUCHANAN | Associate,... | - | - | - | |
| - | ERIC | WEI | Associate,... | - | - | - | |
| - | MEREDITH | COLLINS | Associate ... | - | - | - | |
| - | DAVID | MIGL, PhD | Analyst | - | - | - | |
| - | NICHOLAS | SURDEL, Ph... | Associate | - | - | - | |
| - | TOBIAS | KAISER, Ph... | Associate | - | - | - | |
| - | KRIS | SHUMAN | Associate,... | - | - | - | |
| - | JACQUELINE | RHUDA | Analyst, Q... | - | - | - | |
| - | BRETT | NOEL, PhD,... | Infectious... | - | - | - | |
| - | JONATHAN | LANDESMAN | Director o... | - | - | - | |
| - | MARIO | BARRO, PhD | Head of In... | - | - | - | |
| - | ALEX | ZHANG, MBA | Vice Presi... | - | - | - |
Show more
Mentions in press and media 196
| Date | Title | Description |
| 16.09.2026 | Planted Receives $31.8M Funding Round | OAKLAND, CA, Planted has raised $31.8 million to scale autonomous power deployment. >> Click here for more funding data on Planted Solar >> To export Planted Solar funding data to PDF and Excel, click here Piva Capital and RA C... |
| 09.09.2026 | Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy | Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer ... |
| 09.09.2026 | Venture Capital & Startup Funding Roundup, September 9, 2026: Coatue, Andreessen Horowitz, Greylock, Kleiner Perkins, Sequoia & More | Venture capital’s center of gravity today isn’t in one neat category called AI. It is moving toward companies that control high-value workflows: legal work, sales, wealth management, cybersecurity, industrial production and even weather-ris... |
| 03.09.2026 | Superluminal Medicines Raises $60M in Series B Funding | Superluminal Medicines, a Boston, MA-based biotechnology company integrating AI/ML, protein dynamics, and structural biology to generate G protein-coupled receptor (GPCR) targets, raised $60M in Series B financing. The round was led by BVF ... |
| 02.09.2026 | Reframe Systems Boosts Automated Home Construction with $40M Investment | Reframe Systems secured $40 million in new funding. This capital injection, led by Energy Impact Partners, will accelerate the company's mission. Reframe leverages robotics and software-driven microfactories. It aims to industrialize home c... |
| 02.09.2026 | Typewriter Therapeutics Raises $56M in Series A Funding | Typewriter Therapeutics, a Cambridge, MA-based provider of a gene writing technology platform for genetic medicines, raised $56M in Series A financing. The round was led by AN Venture Partners and RA Capital Management with participation fr... |
| 01.09.2026 | Reframe Systems Raises $40M in Additional Funding | Reframe Systems, a Boston, MA-based physical AI company industrializing home construction, raised $40M in additional funding. The round was led by Energy Impact Partners (EIP), with participation from Counterpart Ventures, E12 Ventures, Glo... |
| 01.09.2026 | AusperBio Inks $120 Million Series C Financing | SAN FRANCISCO, CA, AusperBio Therapeutics, a near-commercial biopharmaceutical company, announced the closing of its $120 million Series C financing. >> Click here for more funding data on AusperBio >> To export AusperBio fundi... |
| 31.08.2026 | Reframe Systems Raises $40M to Scale AI-Powered Homebuilding | Reframe Systems Raises $40M to Expand Robotics Homebuilding Reframe Systems has raised $40 million to expand its robotics-enabled approach to home construction. The round was led by Energy Impact Partners, with participation from Counterpar... |
| 30.08.2026 | AusperBio Secures $120M, Propels AHB-137 to Phase 3 for Hepatitis B Functional Cure | AusperBio secured $120 million Series C, raising total capital to $360 million. This substantial funding accelerates its lead candidate, AHB-137, into a pivotal Phase 3 program for chronic hepatitis B. The company aggressively pursues a fun... |
| 28.08.2026 | AusperBio Raises $120M in Series C Funding | AusperBio, a San Francisco, CA-based biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, raised $120M in Series C financing. The round was ... |
| 28.08.2026 | AusperBio Raises $120 Million Series C As Total Funding Reaches $360 Million And AHB-137 Advances Through Phase 3 | AusperBio has closed a $120 million Series C financing to advance its chronic hepatitis B pipeline, including the Phase 3 registrational program and potential commercialization of its lead investigational therapy AHB-137. The financing brin... |
| 28.08.2026 | AusperBio Raises $120 Million To Push a Hepatitis B Functional Cure | Chronic hepatitis B affects over 250 million people in the world. What’s available as the solution today can only manage the virus, it can rarely cure it. So, most patients end up depending on drugs for life. To solve this, Ausperbio raises... |
| 25.08.2026 | LifeMine Therapeutics Secures Landmark Funding, Reshaping Transplant Medicine | LifeMine Therapeutics secured $263 million. This landmark funding fuels a revolution in organ transplant medicine. The company's lead asset, LIFE-001, offers a next-generation approach. It targets rejection without severe toxicities. Tradit... |
| 19.08.2026 | LifeMine Therapeutics Secures $263M Series D & E | WATERTOWN, MA, LifeMine Therapeutics, a clinical-stage biopharmaceutical company, announced $263 million in financing. >> Click here for more funding data on LifeMine Therapeutics >> To export LifeMine Therapeutics funding data... |
| 18.08.2026 | Abcuro Raises $66M in Series D Funding | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, raised $66M in Series D funding. The round was led by New Leaf Ve... |
| 16.08.2026 | Infinimmune Secures $75M to Propel Human Antibody Therapeutics | Infinimmune secures $75 million in Series A funding. This capital fuels the company's human-first antibody pipeline. Lead candidates target atopic dermatitis. Clinical trials for these programs are expected in 2027. Regeneron Ventures and P... |
| 12.08.2026 | Plantible Foods Secures $35M: Propelling Sustainable Protein Innovation | Plantible Foods secured $35 million in debt and equity funding. This capital fuels a rapid five-fold expansion. Its Eldorado, Texas facility will boost Rubi Protein production. Annual output will now exceed 1,000 metric tons. Funds also tar... |
| 12.08.2026 | Infinimmune Raises $75M in Series A Funding | Infinimmune, an Alameda, CA-based biotechnology company developing antibody therapeutics derived directly from the human immune system, raised $75M in Series A funding. The round was co-led by Regeneron Ventures and Playground Global with p... |
| 10.08.2026 | Plantible Foods Raises $35M in Funding | Plantible Foods, an Eldorado, Texas-based biology food company, raised $35M in combined debt and equity financing. Backers included X-Caliber Rural Capital, providing $25M in debt financing via the USDA OneRD Business & Industry program... |
| 10.08.2026 | Expedition Therapeutics Closes $115 Million Series B | SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B f... |
| 09.08.2026 | Expedition Therapeutics Lands $115M Series B | SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round. >> Click here for more funding data on Expedition Therapeutics >> To export Expedition Therapeutic... |
| 07.08.2026 | LifeMine Therapeutics Raises $263M in Funding | LifeMine Therapeutics Inc., a Watertown, MA-based clinical-stage biopharmaceutical company leveraging digital genomics research technology, has raised $263M in funding. The round included a $188M Series E financing led by Milky Way Investme... |
| 06.08.2026 | Plantible raises $35m in debt, equity, to increase RuBisCO protein production fivefold | Plantible Foods—a startup extracting RuBisCO, a highly-functional protein from fast-growing aquatic plant lemna (duckweed)—has raised $35 million in debt and equity funding to expand operations at its site in Eldorado, Texas. The package in... |
| 06.08.2026 | USDA-Backed Loan Helps Plantible Foods Raise $35M to Scale Up Rubisco Protein Fivefold | 4 Mins Read Californian startup Plantible Foods has secured $35M in USDA-backed loan and equity funding to quintuple the manufacturing capacity for its duckweed-derived Rubisco protein. A funding effort supported by the US government will h... |
| 05.08.2026 | Expedition Therapeutics Raises $115M in Series B Funding | Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, Sofinnova Investments, Nov... |
| 13.07.2026 | Agenus Announces Up To $340 Million Private Placement To Advance ROBBIN Trial | Agenus announced that it entered into a securities purchase agreement for an oversubscribed private placement of approximately $85 million in upfront gross proceeds and up to an additional $255 million if purchase warrants are fully exercis... |
| 11.07.2026 | Alchemab Secures £25M Series A Extension, Fuels AI-Driven Antibody Pipeline | Alchemab Therapeutics landed a substantial £25M Series A extension. The British Business Bank led this pivotal investment. It pushes Alchemab's total Series A funding to an impressive £109M. This capital injection accelerates the Cambridge,... |
| 10.07.2026 | Alchemab Therapeutics Extends Series A Financing with USD34M | Alchemab Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company, raised £25M (USD$34M) in Series A extension funding from British Business Bank. Current investors included SV Health Investors and the Dementia Discovery Fun... |
| 02.07.2026 | Celea Therapeutics Raises $180M in Financing | Celea Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company dedicated to advancing treatments for people with serious respiratory diseases, closed a $180m financing. Participants included RA Capital Management, Leaps by ... |
| 02.07.2026 | Celea Therapeutics Raises $180 Million To Advance Deupirfenidone As Potential New Standard Of Care For IPF | Celea Therapeutics announced the completion of a $180 million financing round to support the development of deupirfenidone, also known as LYT-100, as a potential new standard of care for idiopathic pulmonary fibrosis (IPF). The financing in... |
| 30.06.2026 | NorthLinks Bio Debuts With $34M For Broad-Spectrum Antiviral | NorthLinks Bio emerges with $34M funding from RA Capital. The clinical-stage biotech focuses on broad-spectrum antiviral preventatives. Its lead, intranasal HEX17, targets respiratory viral entry. HEX17 completed Phase 2a, demonstrating a 5... |
| 25.06.2026 | NorthLinks Bio Launches With $34 Million Financing | NorthLinks Bio announced its launch and the completion of a $34 million financing from RA Capital Management. NorthLinks Bio is a clinical-stage biotechnology company developing broad-spectrum antiviral preventive medicines for respiratory ... |
| 25.06.2026 | Ollin Biosciences Raises $330 Million Series B To Advance OLN324 | Ollin Biosciences announced that it raised an oversubscribed $330 million Series B financing round. The round was co-led by new investor TCGX and founding investor ARCH Venture Partners. Participants included a16z Bio+Health, Blackstone Mul... |
| 23.06.2026 | NorthLinks Bio Secures $34M in Funding | NorthLinks Bio, a Boston, Massachusetts-based and Scottish-founded clinical-stage biotechnology company developing broad-spectrum antiviral preventative medicines, officially launched after securing $34m in funding. RA Capital Management ma... |
| 21.06.2026 | Memento Medicines Raises $93 Million Series A For Retinal Disease Therapy | Memento Medicines announced the completion of a $93 million Series A financing round to advance MMT-205, its lead biologic therapy for retinal diseases. The round was co-led by Forbion, RA Capital Management, and Avego BioScience Capital, w... |
| 19.06.2026 | Memento Medicines Raises $93M in Series A Funding | Memento Medicines, Inc., a Boston, MA-based biotech company developing biologic therapies for retinal diseases, raised $93M in Series A funding. The round was led by Forbion, RA Capital Management and Avego BioScience Capital, with particip... |
| 16.06.2026 | SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine | SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The inv... |
| 10.06.2026 | SonoThera Raises $125 Million Series B To Advance Ultrasound-Mediated Genetic Medicines | SonoThera, a biotechnology company developing ultrasound-mediated nonviral genetic medicines, announced the closing of an oversubscribed $125 million Series B financing round to support the clinical advancement of its lead programs for Duch... |
| 10.06.2026 | SonoThera Raises $125M in Series B Funding | SonoThera, a South San Francisco, CA-based biotechnology company developing new genetic medicines, raised $125M in Series B funding. The round was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bay... |
| 01.06.2026 | Secretome Therapeutics Secures $30M, Propels Duchenne Cardiomyopathy Therapy | Secretome Therapeutics closed a $30 million Series A round led by RA Capital. This pivotal funding advances STM-01, an innovative therapy for Duchenne muscular dystrophy-associated cardiomyopathy. The nCPC-derived candidate targets inflamma... |
| 28.05.2026 | Secretome Therapeutics: $30 Million Series A Raised To Advance Duchenne-Associated Cardiomyopathy Therapy | Secretome Therapeutics, a clinical-stage biotechnology company developing therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30 million Series A financing led solely by RA Capital Management. The fu... |
| 28.05.2026 | Secretome Therapeutics Raises $30M in Series A Funding | Secretome Therapeutics, a Plano, TX-based clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), raised $30M in Series A funding. The round was led by RA Capital. David Lubner ... |
| 11.05.2026 | CellCentric Secures $220M to Accelerate Myeloma Drug Inobrodib | CellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated sign... |
| 07.05.2026 | Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation | CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the app... |
| 07.05.2026 | CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple Myeloma | CellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma. The finan... |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 05.05.2026 | Windward Bio secures USD 165 million to advance clinical trials | WIN378, Windward's lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression ... |
| 18.04.2026 | Terremoto Biosciences: $108 Million Series C Raised To Advance AKT1-Selective Oncology And Rare Disease Programs | Terremoto Biosciences, a clinical-stage biotechnology company focused on highly selective small molecule therapies, announced it has closed a $108 million Series C financing to advance its pipeline targeting cancer and rare diseases. The ro... |
| 15.04.2026 | Terremoto Biosciences Raises $108M in Series C Funding | Terremoto Biosciences, a San Francisco, CA-based biotechnology company developing highly targeted, small molecule medicines, raised $108M in Series C funding. Backers included new investors RA Capital Management, Deep Track Capital, Osage U... |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 30.03.2026 | Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI Power | Pinnacle Medicines, a Doylestown, PA biotech, closed an oversubscribed $89 million Series B funding round. This significant capital injection accelerates its oral peptide therapeutics pipeline. The company targets immunology and cardiometab... |
| 29.03.2026 | Pinnacle Medicines: $89 Million Series B Raised For Oral Peptide Therapeutics Development | Pinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and F... |
| 26.03.2026 | Pinnacle Medicines Raises $89M in Series B Funding | Pinnacle Medicines, a Doylestown, PA-based biotechnology company developing oral peptide therapeutics, raised $89M in Series B funding. The round was led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA... |
| 15.03.2026 | Equillium: $35 Million Raised For Biotech Therapy Development | Equillium, a biotechnology company developing therapies for severe autoimmune and inflammatory disorders, announced it has raised $35 million through a private investment in public equity (PIPE) financing led by RA Capital Management. Under... |
| 23.02.2026 | Sensei Biotherapeutics Acquires Faeth Therapeutics And Raises $200 Million In Private Placement | Sensei Biotherapeutics announced it has acquired Faeth Therapeutics and secured approximately $200 million in gross proceeds through a concurrent private placement, positioning the combined company to advance its oncology pipeline through k... |
| 18.02.2026 | Sensei Biotherapeutics Acquires Faeth Therapeutics | Sensei Biotherapeutics (Nansdaq: SNSE), a Boston, MA-based provider of cancer therapeutics, acquired Faeth Therapeutics, a Boston, MA-based provider of multi-node therapies targeting tumor metabolism and signaling. The amount of the transac... |
| 17.02.2026 | ILiAD Biotechnologies Secures $115M to Accelerate Advanced Pertussis Vaccine Development | ILiAD Biotechnologies, a clinical-stage biotech firm, raised $115 million in Series B funding. RA Capital Management led the investment. Janus Henderson and BNP Paribas Asset Management Alts also participated. The capital will advance BPZE1... |
| 11.02.2026 | ILiAD Biotechnologies Raises $115M in Series B Funding | ILiAD Biotechnologies, a Weston, FL-based clinical stage biotech company, raised $115M in Series B funding. The round was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Man... |
| 10.02.2026 | ILiAD Biotechnologies: $115 Million Series B Closed To Advance Intranasal Pertussis Vaccine | ILiAD Biotechnologies, an advanced clinical stage biotechnology company focused on preventing and treating disease caused by Bordetella pertussis, announced it has closed an oversubscribed $115 million Series B financing to advance BPZE1, i... |
| 05.02.2026 | Apeiron Labs: $9.5 Million Series A Raised For Scaling Global AUV Network | Apeiron Labs announced it has closed a $9.5 million Series A financing to scale its real-time ocean intelligence platform and expand deployments of its autonomous underwater vehicle networks. The Cambridge, Massachusetts-based company said ... |
| 04.02.2026 | Apeiron Labs Raises $9.5M in Series A Funding | Apeiron Labs, a Cambridge, MA-based company developing a platform to deliver real-time ocean intelligence, raised $9.5M Series A funding. The round was co-led by S2G Investments, RA Capital Management’s Planetary Health Fund, and DYNE Ventu... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 26.01.2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding. Backers included new investors includi... |
| 13.01.2026 | Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement | Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. Th... |
| 12.01.2026 | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases Mon, Jan 12, 2026 13:00 CET Report this content EQT Life Sciences invests in U.S.-based Kinaset Thera... |
| 12.01.2026 | Kinaset Therapeutics Raises $103M in Series B Funding | Kinaset Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $103M in Series B funding. The round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life ... |
| 11.01.2026 | Diagonal Therapeutics Secures $125M to Propel Innovative Antibody Therapies | Diagonal Therapeutics secured $125M Series B funding. This advances DIAG723, a first-in-class clustering antibody. It targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The Watertown biotech corre... |
| 11.01.2026 | Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic | Diagonal Therapeutics announced it has raised $125 million in an oversubscribed Series B financing to advance its lead program, DIAG723, a first-in-class “clustering antibody” designed to correct dysregulated receptor signaling implicated i... |
| 10.01.2026 | Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma | Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development... |
| 09.01.2026 | Diagonal Therapeutics Raises $125M in Series B Financing | Diagonal Therapeutics, a Watertown, MA-based biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, raised $125M in Series B Funding. The round was co-led by ... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing. The round was co-led by RA Capital Management, Fidelity Ma... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 04.11.2025 | Azalea Therapeutics Raises $82M in Series A Funding | Azalea Therapeutics, Inc., a Berkeley, California-based biotechnology company redefining precision genomic medicines in vivo, launched and completed an $82m seed and Series A financing. The funding included a recently closed $65m Series A f... |
| 28.10.2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| 27.10.2025 | Hemab Therapeutics Raises $157M in Series C Financing | Hemab Therapeutics, a Cambridge, MA, and Copenhagen, Denmark-based clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, closed a $157m Series C financing... |
| 27.10.2025 | Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders | Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed fundi... |
| 23.10.2025 | Adcytherix: €105 Million Series A Raised For Advancing Antibody-Drug Conjugate Pipeline And Novel Payload Platform | Adcytherix, a biopharmaceutical company pioneering the design and development of novel antibody-drug conjugates (ADCs), announced the completion of a €105 million (US$122 million) Series A financing round. The funding will accelerate the co... |
| 23.10.2025 | Electra Therapeutics: $183 Million Series C Raised To Advance SIRP-Targeted Therapies For Immune Disorders And Cancer | Electra Therapeutics, a clinical-stage biotechnology company pioneering therapies against novel targets in immunology and cancer, has announced the close of an oversubscribed $183 million Series C financing round. The round was co-led by Ne... |
| 22.10.2025 | Electra Therapeutics Raises $183M in Series C Funding | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, raised $183m in Series C financing. The round was co-led by Nextech... |
| 22.10.2025 | VitriVax: $17.25 Million Series B Closed To Advance Thermostable Single-Shot Vaccine Platform | VitriVax, a biotechnology company developing next-generation vaccine formulation technologies, announced it has raised $17.25 million in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management, LP, with procee... |
| 22.10.2025 | VitriVax Raises $17.25M in Series B Financing | VitriVax, Inc., a Boulder, CO-based vaccine formulation technology company, raised a total of $17.25m in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management-. The company intends to use the proceeds from t... |
| 20.10.2025 | Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London | PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future o... |
| 16.10.2025 | With its notable €105 million raise, French BioTech startup Adcytherix looks to tackle cancer with novel ADC | Marseille-based Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC), has raised €105 million in a Series A financing round to advance its lead candidate and treat high unmet need diseases ... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding. The round was co-led by Sanofi Ventures and Vi... |
| 27.09.2025 | Sparrow Pharmaceuticals: $95 Million Series B Raised For Advancing Targeted Therapy For Type 2 Diabetes | Sparrow Pharmaceuticals, a company focused on developing therapies for cardiometabolic conditions, recently announced the successful completion of a Series B financing round, raising an impressive $95 million. This significant investment wa... |
| 24.09.2025 | Sparrow Pharmaceuticals Raises $95M in Series B Financing | Sparrow Pharmaceuticals, a Portland, OR-based cardiometabolic therapeutics company, raised $95M Series B financing. The round was co-led by RA Capital Management and Forbion with participation from existing investors including OrbiMed, Rive... |
| 09.09.2025 | Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension | Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 fir... |
| 09.09.2025 | Alchemab Therapeutics Raises Series A Extension Financing | Alchemab Therapeutics, a London, UK-based biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, raised an undisclosed amount in Series A extension funding. Backers inc... |
| 27.08.2025 | Reframe Systems: $20 Million Series A Raised For Scaling Microfactories To Address Housing Crisis | Reframe Systems, a company utilizing physical AI to address the housing crisis, announced a $20 million Series A funding round co-led by Eclipse and VoLo Earth Ventures, with support from MassMutual Catalyst Funds, Cubit Capital, Planetary ... |
| 13.08.2025 | Gameto: $44 Million Series C Raised For Developing Stem Cell-Derived Therapies For Reproductive Health | Gameto is a biotechnology company that is developing therapies using stem cells for reproductive health. The company recently raised $44 million in a Series C financing round, led by Overwater Ventures, with support from several investors, ... |
| 12.08.2025 | Gameto Raises $44M in Series C Funding | Gameto, an Austin, TX-based clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, raised $44M in Series C funding. The round was led by Overwater Ventures, with participation from Insight Partn... |
| 12.08.2025 | FemTech: Gameto Secures $44M to Advance Stem Cell Therapy for Infertility and Menopause | What You Should Know: – Gameto, a clinical-stage biotechnology company focused on reproductive health secures $44M in Series C funding, bringing its total capital raised to a leading $127M. – The funding, led by Overwater Ventures with part... |
| 07.08.2025 | Pahr Therapeutics: $14 Million Seed Funding Raised For Developing Treatments For Pulmonary Arterial Hypertension | Pahr Therapeutics has announced a $14 million seed financing round led by RA Capital Management, AN Venture Partners, and the University of Tokyo Edge Capital Partners (UTEC). Founded in the Raven incubator of RA Capital Management and led ... |
| 30.07.2025 | Pahr Therapeutics: $14 Million Seed Funding Raised For Pulmonary Arterial Hypertension Treatments | Pahr Therapeutics has raised $14 million in a seed financing round to develop therapies for pulmonary arterial hypertension (PAH), led by RA Capital Management, AN Venture Partners, and the University of Tokyo Edge Capital Partners (UTEC). ... |
| 29.07.2025 | Pahr Therapeutics Raises $14M in Seed Funding | Pahr Therapeutics, a Boston, MA- and Osaka, Japan-based clinical stage company developing therapies for PAH, raised $14M in Seed funding. The round was led by RA Capital Management, AN Venture Partners and University of Tokyo Edge Capital P... |
| 24.07.2025 | RA Capital Management: $120 Million Planetary Health Fund Closed | RA Capital Management closed its first Planetary Health Fund (PHF) with $120 million to invest in high-growth companies that enhance resource access, energy innovation, and industrial efficiency. The fund promotes scalable solutions that su... |
| 13.06.2025 | Commons Clinic Secures $26M to Revolutionize Preventative Healthcare | In a world where healthcare often feels fragmented, Commons Clinic is stitching together a cohesive fabric of care. The Los Angeles-based company recently secured $26 million in Series B funding, pushing its total capital to over $60 millio... |
Show more